PT  - JOURNAL ARTICLE
AU  - Long, Quan-xin
AU  - Deng, Hai-jun
AU  - Chen, Juan
AU  - Hu, Jie-li
AU  - Liu, Bei-zhong
AU  - Liao, Pu
AU  - Lin, Yong
AU  - Yu, Li-hua
AU  - Mo, Zhan
AU  - Xu, Yin-yin
AU  - Gong, Fang
AU  - Wu, Gui-cheng
AU  - Zhang, Xian-xiang
AU  - Chen, Yao-kai
AU  - Li, Zhi-jie
AU  - Wang, Kun
AU  - Zhang, Xiao-li
AU  - Tian, Wen-guang
AU  - Niu, Chang-chun
AU  - Yang, Qing-jun
AU  - Xiang, Jiang-lin
AU  - Du, Hong-xin
AU  - Liu, Hua-wen
AU  - Lang, Chun-hui
AU  - Luo, Xiao-He
AU  - Wu, Shao-bo
AU  - Cui, Xiao-ping
AU  - Zhou, Zheng
AU  - Wang, Jing
AU  - Xue, Cheng-jun
AU  - Li, Xiao-feng
AU  - Wang, Li
AU  - Tang, Xiao-jun
AU  - Zhang, Yong
AU  - Qiu, Jing-fu
AU  - Liu, Xia-mao
AU  - Li, Jin-jing
AU  - Zhang, De-chun
AU  - Zhang, Fan
AU  - Cai, Xue-fei
AU  - Wang, De-qiang
AU  - Hu, Yuan
AU  - Ren, Ji-hua
AU  - Tang, Ni
AU  - Liu, Ping
AU  - Li, Qin
AU  - Huang, Ai-long
TI  - Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice
AID  - 10.1101/2020.03.18.20038018
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20038018
4099  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038018.short
4100  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038018.full
AB  - Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice.Methods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test.Results The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of seroconversion for both lgG and IgM was 13 days after symptoms onset. Seroconversion of IgM occurred at the same time, or earlier, or later than that of IgG. IgG levels in 100% patients (19/19) entered a platform within 6 days after seroconversion. The criteria of ‘IgG seroconversion’ and ‘> 4-fold increase in the IgG titers in sequential samples’ together diagnosed 82.9% (34/41) of the patients. Antibody test aided to confirm 4 patients with COVID-19 from 52 suspects who failed to be confirmed by RT-PCR and 7 patients from 148 close contacts with negative RT-PCR.Conclusion IgM and IgG should be detected simultaneously at the early phase of infection. The serological diagnosis criterion of seroconversion or the ‘>; 4-fold increase in the IgG titer’ is suitable for a majority of COVID-19 patients. Serologic test is helpful for the diagnosis of SARS-CoV-2 infection in suspects and close contacts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Emergency Project from the Science & Technology Commission of Chongqing; The Major National S&T program grant (2017ZX10202203 and 2017ZX10302201) from Science & Technology Commission of China; The grant (81871635, 81671997 and 81902060) from the National Natural Science Foundation of China, and the grant (20180141 and 20170413) from the Science & Technology Commission of Yuzhong district, Chongqing.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available.